Cesca Therapeutics, formerly ThermoGenesis (NASDAQ:KOOL), has completed a merger with TotipotentRX in exchange for approximately 12,490,800 shares.
The merged company also changed its name to Cesca Therapeutics and will continue to trade under the NASDAQ ticker symbol KOOL.
“By combining our technologies and solutions for the processing, preparation and preservation of cell-based products with TotipotentRX’s extensive experience in developing clinically validated therapeutic protocols and cell therapy kits for major therapeutic areas, we believe Cesca Therapeutics will become the only fully integrated regenerative medicine company in the world,” CEO Matthew Plavan said in a statement
“As the market continues to grow, we believe this combination offers tremendous potential for shareholder value creation,” he added.
TotipotentRX has developed eight autologous cell therapies in various stages of clinical development targeting areas of high unmet medical need, including critical limb ischemia, acute myocardial infarction, and other vascular and orthopedic diseases. TotipotentRX has the world’s only CRO specializing in cellular therapeutic development services.
Mr. Plavan will serve as CEO of the new company and Kenneth Harris, formerly CEO of TotipotentRX, as president and will join the board. Mitchel Sivilotti will join as Chief Biologist, SVP.
